Scarica l'app Stockscreener
14.54
3.71%
-0.56
Pre-mercato:
14.57
0.03
+0.21%
Precedente Chiudi:
$15.10
Aprire:
$15.11
Volume 24 ore:
305.96K
Relative Volume:
0.68
Capitalizzazione di mercato:
$1.09B
Reddito:
$62.71M
Utile/perdita netta:
$-112.51M
Rapporto P/E:
-9.6291
EPS:
-1.51
Flusso di cassa netto:
$-96.01M
1 W Prestazione:
+3.49%
1M Prestazione:
+9.08%
6M Prestazione:
+7.15%
1 anno Prestazione:
+27.66%
Intervallo 1D:
$14.54
$15.28
Intervallo di 1 settimana:
$13.48
$15.38
Portata 52W:
$9.03
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.54 | 1.06B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Iniziato | TD Cowen | Buy |
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Implied Analyst Target Price of $70.96 for iShares Morningstar Small-Cap ETF (ISCB) Suggests 16% Gain Potential. - AInvest
Zymeworks to Engage in Key Investor Conferences - TipRanks
Zymeworks to Participate in Upcoming Investor Conferences. - AInvest
Zymeworks' Strategic Momentum in 2025: A High-Conviction Biotech Play in the ADC and Bispecific Antibody Space - AInvest
Zymeworks Inc. to Participate in Multiple Upcoming Investor Conferences in September 2025 - Quiver Quantitative
Zymeworks to Present at Several Upcoming Investor Conferences - AInvest
Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Clinical-Stage Biotech Zymeworks Lines Up 4 Major Wall Street Healthcare Conference Presentations in September - Stock Titan
RSI Crosses Above 30 for Zymeworks Inc. — Reversal in SightPortfolio Value Report & Weekly Watchlist of Top Performers - 선데이타임즈
Short Interest Drops in Zymeworks Inc. After RallyMarket Growth Review & Fast Moving Market Watchlists - newsimpact.co.kr
Is Zymeworks Inc. stock forming a triangle patternJuly 2025 Action & AI Forecast Swing Trade Picks - sundaytimes.kr
What is the cash position of Zymeworks Inc.2025 Winners & Losers & Weekly Momentum Stock Picks - mustnews.co.kr
Zymeworks Inc. Revenue Forecasts Upgraded by 44%: Analysts See Substantial Growth Ahead - AInvest
Growth Investors: Industry Analysts Just Upgraded Their Zymeworks Inc. (NASDAQ:ZYME) Revenue Forecasts By 44% - Yahoo Finance
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - Caledon Enterprise
Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression - MSN
Will Breakout in Zymeworks Inc. Sustain Through Next WeekJuly 2025 Drop Watch & Free Technical Pattern Based Buy Signals - beatles.ru
Screener Results Flag Zymeworks Inc. as OversoldTrade Risk Assessment & Free Reliable Trade Execution Plans - thegnnews.com
Short Term Charts Align With Long Term Uptrend in Zymeworks Inc.July 2025 Review & Long-Term Capital Growth Strategies - sundaytimes.kr
Zymeworks Inc. Added to Custom Quant Screener Today2025 Buyback Activity & Free Fast Entry Momentum Trade Alerts - thegnnews.com
Zymeworks (ZYME) Is Up 12.3% After Board Shakeup, Insider Investment, and Return to Profitability – Has The Bull Case Changed? - simplywall.st
Zymeworks (NASDAQ:ZYME) Issues Earnings Results - MarketBeat
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Zymeworks Inc. (NASDAQ:ZYME) Q2 2025 Earnings Call Transcript - Insider Monkey
Zymeworks Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - 富途牛牛
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry - Ariva
Zymeworks Strengthens Leadership with New Board Appointments - TipRanks
Zymeworks Expands Board with Financial Veterans Greg Ciongoli and Robert E. Landry - The Indian Awaaz
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry | ZYME Stock News - GuruFocus
Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors - Quiver Quantitative
Zymeworks appoints two new directors to strengthen board By Investing.com - Investing.com Canada
Zymeworks appoints two new directors to strengthen board - Investing.com India
Zymeworks Strengthens Board with Healthcare Veterans as Key Trial Results Near - Stock Titan
Will breakout in Zymeworks Inc. lead to full recoveryFree Breakout Entry Signal Confirmation Tool - Newser
Has Zymeworks Inc. formed a bullish divergenceLow Risk Stock Selection Strategy Guide - Newser
Zymeworks Inc. stock trendline breakdownFree Scalable Portfolio Growth Suggestions - Newser
Zymeworks Inc. stock outlook for YEARWealth Accumulation Outlook for Safe Investors - Newser
Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates - simplywall.st
Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - Yahoo Finance
Is Zymeworks Inc. forming a breakout patternDouble Capital Strategy Picks - thegnnews.com
Can Zymeworks Inc. hit a new high this monthFree Proven Entry Plan With Low Risk Trade - Newser
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Applying sector rotation models to Zymeworks Inc.Technical Reversal Setup with Risk Limits - Newser
What does recent volatility data suggest for Zymeworks Inc.Stock Price Prediction Using AI Tools - Newser
Why Zymeworks Inc. stock attracts strong analyst attentionFree High Yield Stocks With Buy Confirmation - Newser
Is Zymeworks Inc. affected by consumer sentimentStock Picks with 300% Gain - sisaissue.com
Zymeworks Q2 2025 Earnings Call: Capitalizing on Platform-Driven Innovation and Strategic Execution - AInvest
Zurcher Kantonalbank Zurich Cantonalbank Purchases 4,920 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks (NASDAQ:ZYME) Lowered to “Hold” Rating by Wall Street Zen - Defense World
Zymeworks Reports Strong Q2 2025 Financial Performance - The Globe and Mail
Zymeworks Reports Q2 Results and FDA Clearance - The Globe and Mail
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Zymeworks Inc. Azioni (ZYME) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
May 19 '25 |
Buy |
11.78 |
5,919 |
69,738 |
17,883,908 |
| EcoR1 Capital, LLC | Director |
Apr 16 '25 |
Buy |
11.16 |
73,953 |
825,589 |
17,773,727 |
| EcoR1 Capital, LLC | Director |
Apr 17 '25 |
Buy |
11.52 |
54,760 |
630,819 |
17,828,487 |
| EcoR1 Capital, LLC | Director |
Apr 04 '25 |
Buy |
11.17 |
196,438 |
2,193,800 |
17,699,774 |
| EcoR1 Capital, LLC | Director |
Apr 03 '25 |
Buy |
11.84 |
120,770 |
1,430,170 |
17,503,336 |
| EcoR1 Capital, LLC | Director |
Apr 02 '25 |
Buy |
11.85 |
74,360 |
881,017 |
17,382,566 |
| EcoR1 Capital, LLC | Director |
Apr 01 '25 |
Buy |
11.60 |
48,658 |
564,647 |
17,308,206 |
| EcoR1 Capital, LLC | Director |
Mar 31 '25 |
Buy |
11.75 |
4,397 |
51,658 |
17,259,548 |
| EcoR1 Capital, LLC | Director |
Mar 25 '25 |
Buy |
12.91 |
53,501 |
690,452 |
17,211,303 |
| EcoR1 Capital, LLC | Director |
Mar 26 '25 |
Buy |
12.24 |
43,848 |
536,857 |
17,255,151 |
1.38%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):